Full Press Release Details
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Engineering the Alpha Advantage in Targeted Oncology
Unlocking New Treatment Options Across Solid Tumors:
Optimizing the Entire System
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Optimizing Structural Chemistry:
Choosing The Right Isotope
Not All ²¹²Pb Programs Are Created Equal
Advancing a Theranostic Approach:
Solid Tumors are an Attractive Market for Radiopharmaceuticals
Expanding the Addressable Market
Direct-to-Hospital Delivery through Integrated Isotope Production
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
Reaching the Largest Addressable Market with Regional Manufacturing
Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
VMT- -NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT- -NET in NETs
VMT- -NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis
Patient Exposure and Follow-up with [212Pb]VMT- -NET in ASCO 2026 Data Analysis
VMT- -NET Responses Deepen Over Time
VMT- -NET: Durable Disease Control Across All Doses
Spider Plot of Tumor Change Over Time by Patient
Best-in-class Safety Profile1
Blood Creatinine During Follow-up for All Patients Treated (n=68)
VMT- -NET's Compelling Profile Supports Potential Registration Study at Current Dose Level
Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01
Treatment Emergent Adverse Events (All Grades, Occurring in 10% of Patients)
VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
FAP- is an Attractive Cancer Target with Broad Solid Tumor Potential
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP- for Solid Tumors
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
A Decade of Deliberate, End-to-End Engineering
Built Over a Decade:
Patient with Confirmed PR After [212Pb]VMT- -NET Treatment
Refractory Metastatic Melanoma Trials
ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma
Construct designed for better clinical outcome
212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors